Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Sep 10:2024.09.09.24313375.
doi: 10.1101/2024.09.09.24313375.

Reconciling heterogeneous dengue virus infection risk estimates from different study designs

Affiliations

Reconciling heterogeneous dengue virus infection risk estimates from different study designs

Angkana T Huang et al. medRxiv. .

Update in

  • Reconciling heterogeneous dengue virus infection risk estimates from different study designs.
    Huang AT, Buddhari D, Kaewhiran S, Iamsirithaworn S, Khampaen D, Farmer A, Fernandez S, Thomas SJ, Rodriguez-Barraquer I, Hunsawong T, Srikiatkhachorn A, Ribeiro Dos Santos G, O'Driscoll M, Hamins-Puertolas M, Endy T, Rothman AL, Cummings DAT, Anderson K, Salje H. Huang AT, et al. Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2411768121. doi: 10.1073/pnas.2411768121. Epub 2024 Dec 31. Proc Natl Acad Sci U S A. 2025. PMID: 39739790 Free PMC article.

Abstract

Uncovering rates at which susceptible individuals become infected with a pathogen, i.e. the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population. For dengue, reconstructing exposure and susceptibility statuses from the measured FOI is of particular significance as prior exposure is a strong risk factor for severe disease. FOI can be measured via many study designs. Longitudinal serology are considered gold standard measurements, as they directly track the transition of seronegative individuals to seropositive due to incident infections (seroincidence). Cross-sectional serology can provide estimates of FOI by contrasting seroprevalence across ages. Age of reported cases can also be used to infer FOI. Agreement of these measurements, however, have not been assessed. Using 26 years of data from cohort studies and hospital-attended cases from Kamphaeng Phet province, Thailand, we found FOI estimates from the three sources to be highly inconsistent. Annual FOI estimates from seroincidence was 2.46 to 4.33-times higher than case-derived FOI. Correlation between seroprevalence-derived and case-derived FOI was moderate (correlation coefficient=0.46) and no systematic bias. Through extensive simulations and theoretical analysis, we show that incongruences between methods can result from failing to account for dengue antibody kinetics, assay noise, and heterogeneity in FOI across ages. Extending standard inference models to include these processes reconciled the FOI and susceptibility estimates. Our results highlight the importance of comparing inferences across multiple data types to uncover additional insights not attainable through a single data type/analysis.

Keywords: catalytic model; dengue force of infection; seroincidence; seroprevalence.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Study data.
a) Map of Kamphaeng Phet province showing spatial coverage of cohort studies (colored) and location of Kamphaeng Phet Provincial Hospital (KPPH, blue point). b) Number of bleeds by year (top) and percentages of with GMT>=10 by age and year of collection (bottom). c) Number of dengue cases reported at KPPH per thousand population by year (top), and by year and age (bottom).
Figure 2.
Figure 2.. Estimates from standard force of infection (FOI) inference models.
a) Annual FOI estimated from each of the data sources: seroincidence data (red) and seroprevalence data (yellow) using seropositivity threshold of GMT>=10, and case data (blue). Annual FOI estimated from longitudinal samples of KPS1 (black, (7)) are included for comparison. b) Relationship between serology-derived (y-axis, respective colors) and case-derived susceptibility reconstructions (x-axis). Each point in the reconstruction represents the proportion in each age-year that has not been infected with DENV (naive), has been infected by one serotype (monotypic) or more than one serotype (multitypic).
Figure 3.
Figure 3.. Biases in serology-derived force of infection (FOI) using simulated data with known true parameters.
a) Illustration of anti-DENV antibody kinetics as an individual acquires a cross-reactive (CXR) virus infection or vaccination (i.e., not DENV), one DENV infection, and >1 DENV infections. Measured titers distribute around the true underlying titers with variability depending on the assay characteristics. b) Schematic of biases in serology-derived FOI and their correction efficiencies at low and high seropositivity thresholds. c-f) Antibody kinetics, assay characteristics (rows), and distribution of infection risk in age among susceptible individuals (columns) used to generate observed titer measurements and FOI inferred from those respective simulations using standard models for seroincidence (red) and seroprevalence (yellow).
Figure 4.
Figure 4.. Infection risks in Kamphaeng Phet.
a) Distribution of infection risk by age, b) annual per-serotype FOI inferred from the joint serology model (brown) and the extended case-based model (blue), and c) relationships between the susceptibility reconstructions. Each point in the reconstruction represents the proportion in each age-year that has not been infected with DENV (naive), has been infected by one serotype (monotypic) or more than one serotype (multitypic). d) Effects of presumed test positive probabilities in DENV-naives (x-axis) and long-term test positive probabilities in monotypically-infected individuals (y-axis) on the correlation and ratio between temporal FOIs inferred from the extended case-based model and temporal FOIs inferred from a single data source (either seroincidence or seroprevalence at seropositivity threshold of 10) imposed with age-specific risk inferred from the extended case-based model. Test positive probabilities estimated from the joint serology model are annotated as crosses for comparison.

Similar articles

References

    1. Chala B., Hamde F., Emerging and Re-emerging Vector-Borne Infectious Diseases and the Challenges for Control: A Review. Front Public Health 9, 715759 (2021). - PMC - PubMed
    1. Kaslow D. C., Force of infection: a determinant of vaccine efficacy? NPJ Vaccines 6, 51 (2021). - PMC - PubMed
    1. Mueller I., et al., Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc. Natl. Acad. Sci. U. S. A. 109, 10030–10035 (2012). - PMC - PubMed
    1. Wahala W. M. P. B., de Silva A. M., The human antibody response to dengue virus infection. Viruses 3, 2374–2395 (2011). - PMC - PubMed
    1. Katzelnick L. C., et al., Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929–932 (2017). - PMC - PubMed

Publication types

LinkOut - more resources